Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05415774
Other study ID # RC31/21/0609
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 9, 2022
Est. completion date May 10, 2023

Study information

Verified date December 2023
Source University Hospital, Toulouse
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a pilot study on Parkinson's disease patients to evaluate Combined deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus for unresponsive freezing of gait.


Description:

One of the most challenging and unresolved problems in Parkinson's disease (PD) is the treatment of gait disorders, unresponsive to dopaminergic medication. Additionally, PD patients suffering from severe/unresponsive gait disorders are not considered good candidates for subthalamic nucleus deep brain stimulation (STN-DBS). Currently, there are no specific therapies to treat gait disorders in PD with an insufficient response to dopaminergic treatment. Furthermore, axial symptoms develop during disease progression even in operated patients. Axial symptoms are often one of the main causes of disability. There is evidence suggesting that low-frequency (LF) stimulation of the ventral area of the STN can improve axial symptoms. At the same time, the substantia nigra pars reticulata (SNr) is one of the most important output centers of the basal ganglia and is integrated within the locomotor control systems. Neurons within the SNr may act as high-frequency (HF) pacemakers, disrupting normal behavior downstream in the circuit. HF-STN in combination with LF or HF-SNr stimulation have been shown some beneficial effect on freezing of gait (FoG) among PD patients who had FoG unresponsive to dopaminergic therapy. However, only small pilot trials and case series have been investigated this strategy and evidences are scarce. The aim of this study is to evaluate the effect of combined (C) stimulation of the STN and SNr on FoG if compared to standard (S) stimulation of the STN at 130 Hz, over one month. Based on previous literature evidence as primary aim the respective effect of two setting of C-stimulation will be separately assessed: a) C1- stimulation, with HF stimulation of the STN and SNr using a 'interleaved pulses' at 125 Hz vs. S- stimulation, over one month; b) C2-stimulation with LF stimulation of the SNr at 60Hz and HF stimulation of the STN vs. S- stimulation, over one month. Other objectives are to evaluate the: - Tolerance of combined stimulation (STN + SNr) through the collection of adverse events (AEs) - Development of psychic events such as the presence of depression or dysphoria - Effect of C (C1 and C2) -stimulation on walking disorders and other axial symptoms if compared vs. the S-stimulation. - Effect of C (C1 and C2) -stimulation on PD's motor symptoms and motor complications if compared vs. the S-stimulation. - Effect of C (C1 and C2) -stimulation on sleep quality if compared vs. the S-stimulation. Each patient will have the 3 types of stimulation: 1. One month of S-stimulation (130hz, STN). 2. One month of C1- stimulation; 3. One month of C2- stimulation; Stimulation setting order will be randomly assigned. Minimal dopaminergic treatment adjustment will be allowed to minimize the drop-out rate (± 100 mg of levodopa equivalent daily dose) and registered


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date May 10, 2023
Est. primary completion date May 10, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: 1. Idiopathic PD defined as by the MDS Criteria ; 2. Patients submitted to STN-DBS, for at least 6 months; 3. Patients with STN-DBS at 130Hz; 4. Patients with a troublesome FoG according to the "NFOG-Q", Part II Item II = 2 or Part III Item 7 = 2; 5. Mini Mental State (MMS) = 25 ; 6. Ventral contact of electrodes implanted in the SNr (according to analysis of activated tissue volume models (VTA)); 7. Patients with stable parkinsonian stimulation parameters and anti-parkinsonian treatments for one month before the inclusion visit; 8. Patients with H/Y stage = 3 in the Med ON/Stim On condition (at 130Hz, S-stimulation); Exclusion Criteria: 1. Patient with atypical Parkinsonian syndrome; 2. Patient with severe FoG before DBS, i.e. MDS-UPDRS item 2.13 in Med ON =2 or MDS-UPDRS item 3.11 =2 in Med On; 3. Patient whose antiparkinsonian treatments were modified during the last month before inclusion; 4. Patient with H&Y stage =4 in Med On/Stim On (at 130Hz, S-stimulation) ;

Study Design


Related Conditions & MeSH terms


Intervention

Device:
1 : S-C1-C2
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) : Standard stimulation 125Hz at both STN and SNr for C1, 125Hz for STN and 60 for SNr for C2
2 : S-C2-C1
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) : Standard stimulation 125Hz at both STN and SNr for C1, 125Hz for STN and 60 for SNr for C2
3 : C1 - S - C2
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) : Standard stimulation 125Hz at both STN and SNr for C1, 125Hz for STN and 60 for SNr for C2
4 : C1 -C2 - S
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) : Standard stimulation 125Hz at both STN and SNr for C1, 125Hz for STN and 60 for SNr for C2
5 : C2 - S - C1
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) : Standard stimulation 125Hz at both STN and SNr for C1, 125Hz for STN and 60 for SNr for C2
6 : C2 - C1 - S
Deep brain stimulation of the substantia nigra pars reticulata and of the subthalamic nucleus according to the order of randomisation (see intervention name) : Standard stimulation 125Hz at both STN and SNr for C1, 125Hz for STN and 60 for SNr for C2

Locations

Country Name City State
France Uh Toulouse Toulouse

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Score change of the " New freezing of gait questionnaire " the score change of the means of the New freezing of gait questionnaire at the end of each combined C1 and C2 stimulation, compared to S stimulation at one month of each period. The NFOG-Q is a clinician rated instrument used to evaluate FOG severity in patients with PD, unrelated to falls. Item responses use a 5-point scale ranging from 0 (absence of symptom) to 4 (severe). Total score ranges from 0 to 28; higher scores correspond to more severe FOG. Answers are based on experience over the past week or overall FOG during an entire day. ONE MONTH AFTER INCLUSION
See also
  Status Clinical Trial Phase
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A
Enrolling by invitation NCT04560504 - Effectiveness of Oculomotor Training in Parkinson's Disease N/A